Press ReleasesCluePoints, Ken Getz & Tufts CSDD and PwC Unveil New RBQM Insights Report at DIA Global Annual Meeting 2023

CluePoints and partners present and discuss the results of a new study examining RBQM use and adoption.

20 June 2023 -- Pennsylvania, US -- CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality Management Software for clinical trials, will share a first look at industry research at the DIA Global Annual Meeting 2023.

CluePoints will host an exclusive opportunity for RBQM experts to be among the first to hear about the comprehensive use of Risk-Based Quality Management (RBQM) components, implementation best practices and overcoming the challenges of virtual and remote clinical trial technologies. In collaboration with RBQM market leaders CluePoints, Ken Getz and his team at the Tufts Center for the Study of Drug Development (CSDD) and PwC recently conducted an industry-wide survey on RBQM adoption and attitudes. The study, followed by global roundtables with senior RBQM executives, has uncovered fascinating insights into increasing RBQM adoption and advancements in the approach driven by technology.

Ken Getz, alongside CluePoints co-founders Patrick Hughes and Francois Torche & Steve Young, chief scientific officer, will take part in a fireside chat to present and discuss a first look at the new research findings at an exclusive experts’ dinner. Taking place on Monday 26 June, from 7pm EDT, the exclusive session titled Fireside Chat: RBQM Adoption — Current Use, Overcoming Barriers and Anticipating ICH E6 (R3) will provide:

  • A first-hand look at new Tufts CSDD research measuring comprehensive adoption and overcoming challenges associated with RBQM.
  • Gaining an understanding of the ongoing shift to new clinical trial execution models.
  • What are the implications of the recent ICH E6 (R3) regulatory guidance updates related to the research? We’ll take a look.

Steve Young, chief scientific officer at CluePoints, commented: “These findings are even more intriguing in light of the recent regulatory guidance ICH E6 (R3) updates. We welcome opportunities to begin discussing how the new guidelines correlate to the research with all DIA delegates.”

Additionally, from 11:30am to 1pm EDT on Monday 26 June, CluePoints will be hosting 15-minute demos with coffee and pastries provided at their booth, 706. Happy hour demos with cocktails and appetisers will also be available from 3pm to 5pm EDT on Tuesday 27 June. CluePoints’ solution expert and chief product and technology officer will present the demos, which will focus on CluePoints’ market-leading software and they will also discuss where the industry and platform are heading.

All attendees who visit booth 706 will have the opportunity to be entered into a drawing to win an Apple Watch Ultra.

Attendees are also invited to DIA’s most colourful social event – the CluePoints and Phastar co-sponsored party on Tuesday 27 June. The evening will consist of excitement, celebration and valuable networking opportunities from 10pm to 1am EDT at The Grand, Boston. Secure your place at the party by registering here.

The DIA Global Annual Meeting 2023 takes place from 25-29 June in Boston, Massachusetts. View the full meeting programme at and visit booth 706 to chat with the CluePoints team.

About CluePoints
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. Our products utilize comprehensive statistical algorithms to determine clinical trial data quality, accuracy and integrity during and after study conduct. Aligned with guidance from the FDA, EMA and ICH E6 (R2), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management and drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation, you now have everything you need to adhere to global regulatory guidance. The result is increased operational efficiency, lower costs, and reduced regulatory submission risk as part of the industry paradigm shift to RBQM. Visit:


Human-Centred Design: From Inception to Integration

IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process


The Importance of Temperature Control in Pharmaceutical Analysis

As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research


Providing Support Throughout the Patient Journey

Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?